Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
124M
-
Number of holders
-
335
-
Total 13F shares, excl. options
-
136M
-
Shares change
-
+2.13M
-
Total reported value, excl. options
-
$5.82B
-
Value change
-
+$128M
-
Put/Call ratio
-
0.31
-
Number of buys
-
189
-
Number of sells
-
-126
-
Price
-
$42.71
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q4 2020
377 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q4 2020.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 335 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 136M shares
.
Largest 10 shareholders include BlackRock Inc. (18.5M shares), VANGUARD GROUP INC (13.1M shares), Artisan Partners Limited Partnership (10.3M shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (6.36M shares), STATE STREET CORP (5.53M shares), Invesco Ltd. (5.33M shares), JPMORGAN CHASE & CO (5.2M shares), Bellevue Group AG (4.05M shares), SNYDER CAPITAL MANAGEMENT L P (3.3M shares), and GOLDMAN SACHS GROUP INC (2.64M shares).
This table shows the top 335 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.